Smoking Cessation Aids Market Size, Trends and Growth Analysis by 2027

The global market for smoking cessation aids is projected to grow significantly, reaching approximately US$ 64,032.30 million by 2028, up from US$ 23,413.08 million in 2021. This growth represents a compound annual growth rate (CAGR) of 15.5% from 2021 to 2028.

Several key factors are propelling this market's expansion, including the increasing addiction to tobacco products and a surge in initiatives aimed at reducing smoking and tobacco dependence. However, the high costs associated with developing nicotine replacement therapies may pose challenges to market growth in the coming years.

Quitting smoking significantly reduces the risk of developing cancer and other serious health issues. Various products are available to assist individuals in their efforts to stop smoking, some of which contain nicotine while others do not. These aids include counseling, behavioral therapy, medications, and nicotine delivery systems such as patches, gums, lozenges, inhalers, and nasal sprays. The FDA's Center for Drug Evaluation and Research regulates these products to ensure their safety and efficacy, confirming that their benefits outweigh any potential risks.

Globally, both governmental and non-governmental organizations are actively launching campaigns to raise awareness and implement strategies to combat the health issues associated with smoking and tobacco use. These initiatives aim to alleviate the economic and health burdens caused by cigarette smoking in various countries. For example, every year on May 31st, the World Health Organization (WHO) and its partners observe World No Tobacco Day (WNTD), focusing on educating the public about the harmful effects of tobacco and second-hand smoke. The primary goal of this day is to discourage tobacco consumption in all forms and inform individuals about the available aids for smoking cessation.

Anti-smoking campaigns are organized at global, national, and regional levels. A notable example is the "Commit to Quit" campaign launched by the WHO in December 2020, which successfully encouraged around 100 million people worldwide to quit using tobacco. Additionally, in July 2018, the Ministry of Health (MoH) India initiated the "What Damage Will This Cigarette/Bidi Do" campaign, which featured public service announcements urging smokers to consider the severe health risks associated with smoking, including heart attacks, chronic lung diseases, cancer, and premature death. Such increasing efforts by governments and various organizations to promote smoking cessation aids and reduce smoking prevalence are vital for the market's growth.

The smoking cessation aids market is categorized by product type, including nicotine replacement therapies, pharmaceuticals, electronic cigarettes, and other alternatives. Among these, e-cigarettes are emerging as a rapidly growing segment, often viewed as a healthier substitute for traditional tobacco cigarettes. E-cigarettes are effective in mitigating health issues linked to tobacco use, while nicotine replacement therapies are particularly effective for those looking to quit smoking. The appeal of e-cigarettes lies in their reduced harm compared to conventional cigarettes, as they produce no smoke, eliminate the risk of passive smoking, can be used in non-smoking areas, and come in various nicotine levels and flavors. This versatility and the increasing popularity of e-cigarettes, bolstered by their electronic features, are significant factors driving their demand.

The COVID-19 pandemic, which first emerged in December 2019 in Wuhan, China, has had widespread effects across numerous markets, including smoking cessation aids. The WHO has classified COVID-19 as a public health emergency, and research indicates that the use of e-cigarettes, as well as the dual use of e-cigarettes and traditional cigarettes, may be significant risk factors for COVID-19, a connection that had not been previously established. Studies suggest that smoking increases the risk of influenza, as smokers may experience some degree of immunosuppression and produce more mucus, complicating respiratory health.

In preparing the report on the smoking cessation aids market, various secondary sources were consulted, including the European Medicines Agency (EMA), European Union (EU), Organization for Economic Co-operation and Development (OECD), National Institute on Drug Abuse (NIDA), Centers for Disease Control and Prevention (CDC), United Nations Office on Drugs and Crime (UNODC), and the Association for a Drug-Free Society (RNS).